Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 24, 2025 08:30 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
September 22, 2025 09:00 ET | Source: Incyclix Bio

Fierce Biotech names Incyclix Bio a “Fierce 15” Biotech Company of 2025

RESEARCH TRIANGLE PARK, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, today announced that Fierce Biotech has named it as one of 2025’s Fierce 15 biotechnology companies, designating...
September 22, 2025 08:30 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic...
September 22, 2025 06:20 ET | Source: CELLPROTHERA

CellProthera annonce la publication de ses résultats de phase I/IIb sur la sécurité et la faisabilité des ProtheraCytes® chez des patients souffrant d'insuffisance cardiaque sévère après un infarctus du myocarde.

La publication du JACC-Heart Failure souligne la haute qualité de l'expansion cellulaire, la bonne tolérance, le risque procédural gérable et les signes précoces encourageants d'effets fonctionnels. ...
September 22, 2025 06:20 ET | Source: CELLPROTHERA

CellProthera announces peer-reviewed publication of its Phase I/IIb results on safety and feasibility of ProtheraCytes® in patients with severe heart failure post-myocardial Infarction

JACC-Heart Failure publication highlights high-quality cell expansion, good tolerability, manageable procedural risk and encouraging early signals of functional effects. Mulhouse, France – [DATE] –...
September 18, 2025 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

STAFFORD, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
September 17, 2025 10:01 ET | Source: Foundation for Sarcoidosis Research

Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma’s Phase 3 Clinical Trial Results

Foundation for Sarcoidosis Research acknowledges results of aTyr Pharma’s Phase 3 trial of efzofitimod in pulmonary sarcoidosis.
September 17, 2025 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

A certificate of grant for Propanc’s “proenzyme composition” patent was received from the US Patent & Trademark Office.
September 17, 2025 02:00 ET | Source: Opterion Health AG

Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101 in Patients with Advanced Chronic Kidney Disease

MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company developing OPT101 as an innovative treatment for patients on peritoneal...
September 16, 2025 13:00 ET | Source: UTR Therapeutics Inc.

UTR Therapeutics Publishes Landmark Preclinical Data in Frontiers in Pharmacology Supporting IND Submission for First-in-Class c-MYC RNA Therapeutic

UTR Therapeutics Inc Publishes Data supporting US FDA IND for a First-in-Human Clinical Trial of mRNA destabilizing drug targeting c-MYC driven cancer